David A. Karlin

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

L. Coussens, H. Rugo, N. Sharma, 2019, Therapeutic advances in medical oncology.